title: Effectiveness of crizotinib in a patient with ALK IHC-positive/FISH-negative metastatic lung adenocarcinoma.
abstract: We report a case of crizotinib effectiveness in a heavily pretreated patient with a metastatic NSCLC initially considered IHC-positive and FISH-negative for ALK rearrangement. After repeated analyses of tumor samples, borderline ALK FISH-positivity (18.5% positive cells) was demonstrated.
authors.affiliation: Division of Pulmonology, Université catholique de Louvain (UCL), CHU UCL Namur, Yvoir, Belgium.
authors.forename: A
authors.initials: A
authors.lastname: Rosoux
authors.affiliation: Center for Oncologic Research (CORE), Antwerp University, Antwerp, Belgium.
authors.forename: P
authors.initials: P
authors.lastname: Pauwels
authors.affiliation: Division of Pulmonology, Université catholique de Louvain (UCL), CHU UCL Namur, Yvoir, Belgium.
authors.forename: F
authors.initials: F
authors.lastname: Duplaquet
authors.affiliation: Department of Pathology, Université Libre de Bruxelles (ULB), Hôpital Erasme, Brussels, Belgium.
authors.forename: N
authors.initials: N
authors.lastname: D'Haene
authors.affiliation: Department of pathology, UZ Leuven, Leuven, Belgium.
authors.forename: B
authors.initials: B
authors.lastname: Weynand
authors.affiliation: Department of Pathology, UCL, CHU UCL Namur, Yvoir, Belgium.
authors.forename: M
authors.initials: M
authors.lastname: Delos
authors.affiliation: Neo New Oncology GmbH, Cologne, Germany.
authors.forename: R
authors.initials: R
authors.lastname: Menon
authors.affiliation: Neo New Oncology GmbH, Cologne, Germany.
authors.forename: L C
authors.initials: LC
authors.lastname: Heukamp
authors.affiliation: Department of Pathology, VU University, Amsterdam, Netherlands.
authors.forename: E
authors.initials: E
authors.lastname: Thunnissen
authors.affiliation: Division of Pulmonology, Université catholique de Louvain (UCL), CHU UCL Namur, Yvoir, Belgium. Electronic address: sebahat.ocak@uclouvain.be.
authors.forename: S
authors.initials: S
authors.lastname: Ocak
mesh_terms: D000230:Adenocarcinoma / Q000175:diagnosis / Q000188:drug therapy* / Q000235:genetics* / Q000378:metabolism; D000077192:Adenocarcinoma of Lung; D000328:Adult; D000077548:Anaplastic Lymphoma Kinase; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000077547:Crizotinib; D017809:Fatal Outcome; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D017404:In Situ Hybridization, Fluorescence; D008175:Lung Neoplasms / Q000175:diagnosis / Q000188:drug therapy* / Q000235:genetics* / Q000378:metabolism; D009362:Neoplasm Metastasis; D009367:Neoplasm Staging; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D011720:Pyrazoles / Q000627:therapeutic use*; D011725:Pyridines / Q000627:therapeutic use*; D020794:Receptor Protein-Tyrosine Kinases / Q000235:genetics* / Q000378:metabolism
chemical_list: D000970:Antineoplastic Agents; D047428:Protein Kinase Inhibitors; D011720:Pyrazoles; D011725:Pyridines; D000077547:Crizotinib; C000626173:ALK protein, human; D000077548:Anaplastic Lymphoma Kinase; D020794:Receptor Protein-Tyrosine Kinases
keywords: ALK; Crizotinib; Fluorescent in situ hybridization; Immunohistochemistry; Non-small-cell lung cancer